Ganoderma lucidum (lucid ganoderma), a traditional Chinese herb, has been used extensively in East Asian for thousand years, and the biological activities and pharmacological functions of lucid ganoderma have been successively studied. Nowadays, some researches use scientific methods and techniques to study its anticancer effect on the cancer patients in clinical trial. For example, PC-SPES extracted from a mixture of lucid ganoderma and seven herbs decreased the prostate-specific antigen in patients with chemotherapy-induced hormone-independent prostate cancer. Lucid ganoderma extracts also improved the immune-stimulating response, such as the increase of plasma interleukin (IL)-2, IL-6, and interferon-γ concentrations, the enhance of natural killer cell activity, the decrease of plasma IL-1 and tumor necrosis factor-α concentrations, etc, as well as had low adverse effects in the cancer patients. The anticancer effects of lucid ganoderma in cell and animal models could be the strong references for the clinical trials. The components with anticancer potential in lucid ganoderma include triterpenoids, steroids, polysaccharides, fatty acids, and novel proteins such as LZ-8. On the basis of in vitro and in vivo study, the anticancer mechanism of lucid ganoderma treatment against the growth of cancer cells in clinical trial might be mediated by cell cycle arrest, apoptosis, anti-invasion, anti-migration, immunomodulation, anti-angiogenesis, etc. Additionally, the combination from lucid ganoderma and other herbs or foods as an alternative treatment might exhibit synergistic anticancer efficacy. However, more studies regarding the safety and application in clinical trial need to be processed in the future for providing more evidences.